Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• McSorley MA, Alberg AJ, Allen DS, et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int J Cancer. 2009;125(3):674–679. doi:10.1002/ijc.2440619444906
   PubMed Web of Science ®Google Scholar
• Conic I, Dimov I, Tasic-Dimov D, et al. Ovarian epithelial cancer stem cells. Sci World J. 2011;11:1243–1269. doi:10.1100/tsw.2011.112
   Google Scholar
• Liew PL, Hsu CS, Liu WM, et al. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int J Clin Exp Pathol. 2015;8:85642–85649.
   Web of Science ®Google Scholar
• Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–138. doi:10.1016/S0140-6736(10)62231-321183212
   PubMed Web of Science ®Google Scholar
• Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014;20(20):5150–5156. doi:10.1158/1078-0432.CCR-14-131225320365
   PubMed Web of Science ®Google Scholar
• Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–282. doi:10.1038/nrc343223426401
   PubMed Web of Science ®Google Scholar
• Lo KW, Kogoy JM, Pfister KK. The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3. J Biol Chem. 2007;282(15):11205–11212. doi:10.1074/jbc.M61127920017289665
   PubMed Web of Science ®Google Scholar
• Huang X, Wang HL, Qi ST, et al. DYNLT3 is required for chromosome alignment during mouse oocyte meiotic maturation. Reprod Sci. 2011;18(10):983–989. doi:10.1177/193371911140166421693773
   PubMed Web of Science ®Google Scholar
• Yeh TY, Chuang JZ, Sung CH. Dynein light chain rp3 acts as a nuclear matrix-associated transcriptional modulator in a dynein-independent pathway. J Cell Sci. 2005;118(Pt 15):3431–3443. doi:10.1242/jcs.0247216079286
   PubMed Web of Science ®Google Scholar
• Karagoz K, Lehman HL, Stairs DB, et al. Proteomic and metabolic signatures of esophageal squamous cell carcinoma. Curr Cancer Drug Targets. 2016;16(8):721–736. doi:10.2174/1568009616666160203113721
   Web of Science ®Google Scholar
• Shao C, Sun W, Tan M, et al. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res. 2011;17(13):4320–4330. doi:10.1158/1078-0432.CCR-10-299221551254
   PubMed Web of Science ®Google Scholar
• King SM. The dynein microtubule motor. Biochim Biophys Acta. 2000;1496(1):60–75.10722877
   PubMed Web of Science ®Google Scholar
• Sarma NJ, Yaseen NR. Dynein light chain 1 (DYNLT1) interacts with normal and oncogenic nucleoporins. PLoS One. 2013;8(6):e67032. doi:10.1371/journal.pone.006703223840580
   PubMed Web of Science ®Google Scholar
• Cervantes-Anaya N, Ponciano-Gomez A, Lopez-Alvarez GS, et al. Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats. Tumour Biol. 2017;39(4):1–10. doi:10.1177/1010428317695932
   Google Scholar
• Ochiai K, Watanabe M, Ueki H, et al. Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1. Biochem Biophys Res Commun. 2011;412(2):391–395. doi:10.1016/j.bbrc.2011.07.10921835165
   PubMed Web of Science ®Google Scholar
• Kresno SB, Gondhowiardjo S. Disregulation process of cancer cell proliferation. Acta Med Indones. 2004;36(3):169–176.15557688
   PubMedGoogle Scholar
• Bolton WE, Mikulka WR, Healy CG, et al. Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry. 1992;13(2):117–126. doi:10.1002/cyto.9901302031372207
   PubMedGoogle Scholar
• Ma X, Wu Y, Zhang T, et al. Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. J Cancer. 2017;8(18):3828–3837. doi:10.7150/jca.2093529151970
   PubMed Web of Science ®Google Scholar
• Wang X, Wang D, Yuan N, et al. The prognostic value of PCNA expression in patients with osteosarcoma: a meta-analysis of 16 studies. Medicine. 2017;96(41):e8254. doi:10.1097/MD.000000000000825429019895
   PubMed Web of Science ®Google Scholar
• Jurikova M, Danihel L, Polak S, et al. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118(5):544–552. doi:10.1016/j.acthis.2016.05.00227246286
   PubMed Web of Science ®Google Scholar
• Lv Q, Zhang J, Yi Y, et al. Proliferating cell nuclear antigen has an association with prognosis and risks factors of cancer patients: a systematic review. Mol Neurobiol. 2016;53(9):6209–6217. doi:10.1007/s12035-015-9525-326558632
   PubMed Web of Science ®Google Scholar
• Tochhawng L, Deng S, Pervaiz S, et al. Redox regulation of cancer cell migration and invasion. Mitochondrion. 2013;13(3):246–253. doi:10.1016/j.mito.2012.08.00222960576
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100. doi:10.1038/nrc72712635172
   PubMed Web of Science ®Google Scholar
• Alaseem A, Alhazzani K, Dondapati P, et al. Matrix metalloproteinases: a challenging paradigm of cancer management. Semin Cancer Biol. 2019;56:100–115. doi: 10.1016/j.semcancer.2017.11.008.
   Web of Science ®Google Scholar
• Lalita Y, Naveen P, Varun R, et al. Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev. 2014;15(3):1085–1091.24606423
   PubMedGoogle Scholar
• Asier J, Majid M, Susumu A, et al. Fascin regulates nuclear movement and deformation in migrating cells. Dev Cell. 2016;38(4):371–383. doi:10.1016/j.devcel.2016.07.02127554857
   PubMed Web of Science ®Google Scholar
• Min KW, Chae SW, Kim DH, et al. Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett. 2015;10(1):121–130. doi:10.3892/ol.2015.319126170987
   PubMed Web of Science ®Google Scholar
• Onder S, Taskin OC, Sen F, et al. High expression of SALL4 and fascin, and loss of E-cadherin expression in undifferentiated/dedifferentiated carcinomas of the endometrium: an immunohistochemical and clinicopathologic study. Medicine. 2017;96(10):e6248. doi:10.1097/MD.000000000000624828272224
   PubMed Web of Science ®Google Scholar
• Hu W, McCrea PD, Deavers M, et al. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis. 2000;18(1):83–88.11206843
   PubMed Web of Science ®Google Scholar
• Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004;16(5):590–596. doi:10.1016/j.ceb.2004.07.00915363811
   PubMed Web of Science ®Google Scholar
• Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 2010;42(10):1614–1617. doi:10.1016/j.biocel.2010.06.01920601080
   PubMed Web of Science ®Google Scholar
• Ren L, Khanna C. Role of ezrin in osteosarcoma metastasis. Adv Exp Med Biol. 2014;804:181–201. doi:10.1007/978-3-319-04843-7_1024924175
   PubMed Web of Science ®Google Scholar
• Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014;127(Pt 2):267–275. doi:10.1242/jcs.13310824421310
   PubMed Web of Science ®Google Scholar
• Li M, Feng YM, Fang SQ. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017;50(4):e5356. doi:10.1590/1414-431X2017607128355349
   PubMed Web of Science ®Google Scholar
• Jin Q, Liu G, Domeier PP, Ding W, Mulder KM, de Wever O. Decreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells. PLoS One. 2013;8(6):e66439. doi:10.1371/journal.pone.006643923755307
   PubMed Web of Science ®Google Scholar